Proactive Investors - Run By Investors For Investors

Kane Biotech plans to expand commercialization of its anti-microbial biofilm products into Europe

Kane Biotech (TSX-V:KNE, OTCQB:KNBIF) CEO Mark Ahrens-Townsend tells Proactive Investors that the technology company, engaged in the development and commercialization of products that prevent and remove microbial biofilms, is looking to expand into Europe, and potentially further.

Ahrens-Townsend says the company licensed two of their technologies to U.K.-based company Dechra Pharmaceuticals for distribution in the North American veterinary channel, saying Dechra could transport them into the European market.

View full KNE profile View Profile

Kane Biotech Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use